Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000078015 | SCV000109853 | pathogenic | not provided | 2013-11-14 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000672800 | SCV000797943 | likely pathogenic | Argininosuccinate lyase deficiency | 2018-02-15 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000672800 | SCV001388733 | pathogenic | Argininosuccinate lyase deficiency | 2023-10-14 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 8 of the ASL gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ASL are known to be pathogenic (PMID: 2263616, 24166829). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with argininosuccinate lyase deficiency (PMID: 24166829; Invitae). ClinVar contains an entry for this variant (Variation ID: 92365). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000672800 | SCV002814525 | pathogenic | Argininosuccinate lyase deficiency | 2021-12-02 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000672800 | SCV004202378 | pathogenic | Argininosuccinate lyase deficiency | 2023-10-28 | criteria provided, single submitter | clinical testing |